New Analyses Presented At AHA 2017 Show Repatha ® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks

Data Support Use of Repatha to Reduce Risk of Recurrent Cardiovascular Events in Patients With History of Multiple Heart Attacks Additional Analysis Found That Patients With More Recent Heart Attacks Experienced Substantial Risk Reductions With Repatha Repatha Benefit in Peripheral Artery Disease Patients Presented at AHA Scientific Sessions 2017 and Simultaneously Published in "Circulation" THOUSAND OAKS, Calif., Nov. 13, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the addition of Repatha to statin therapy improved clinical outcomes with significa...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news